Comparison 3. All studies: treatment adherence and toxicities.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Participants requiring chemotherapy delays	5	1053	Risk Ratio (M‐H, Fixed, 95% CI)	2.23 [1.70, 2.94]
3.2 Participants requiring dose reduction	8	2055	Risk Ratio (M‐H, Fixed, 95% CI)	1.77 [1.56, 2.02]
3.3 Early cessation of treatment	17	4178	Risk Ratio (M‐H, Fixed, 95% CI)	1.20 [1.04, 1.38]
3.4 Neutropenia	20	4849	Risk Ratio (M‐H, Fixed, 95% CI)	1.53 [1.43, 1.63]
3.5 Febrile neutropenia	12	3771	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.89, 1.49]
3.6 Anaemia	19	4757	Risk Ratio (M‐H, Fixed, 95% CI)	8.20 [5.66, 11.89]
3.7 Thrombocytopenia	19	4731	Risk Ratio (M‐H, Fixed, 95% CI)	7.59 [5.10, 11.29]
3.8 Neuropathy	15	4312	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.95, 1.57]
3.9 Nausea	17	4228	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [1.30, 2.74]
3.10 Renal impairment	4		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.11 Treatment‐related death	11	3176	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.14, 2.33]
3.12 Participants requiring dose reduction – random effects	8	2055	Risk Ratio (M‐H, Random, 95% CI)	2.18 [1.08, 4.41]
3.13 Neutropenia – random effects	20	4849	Risk Ratio (M‐H, Random, 95% CI)	1.68 [1.12, 2.52]